User login
The following reports are based on presentations at the annual meeting of the American Society of Clinical Oncology held May 31-June 4 in Chicago. Many of the presentations heralded a new era of precision medicine, that is, treatment based on patient and tumor genetics, rather than tumor location alone, according to outgoing ASCO president Sandra Swain, MD. Immunotherapies, specifically the PD-L1 antibodies featured prominently.
*Click on the link to the left for a PDF of the full article.
The following reports are based on presentations at the annual meeting of the American Society of Clinical Oncology held May 31-June 4 in Chicago. Many of the presentations heralded a new era of precision medicine, that is, treatment based on patient and tumor genetics, rather than tumor location alone, according to outgoing ASCO president Sandra Swain, MD. Immunotherapies, specifically the PD-L1 antibodies featured prominently.
*Click on the link to the left for a PDF of the full article.
The following reports are based on presentations at the annual meeting of the American Society of Clinical Oncology held May 31-June 4 in Chicago. Many of the presentations heralded a new era of precision medicine, that is, treatment based on patient and tumor genetics, rather than tumor location alone, according to outgoing ASCO president Sandra Swain, MD. Immunotherapies, specifically the PD-L1 antibodies featured prominently.
*Click on the link to the left for a PDF of the full article.